الفهرس 
Prostate Gland and Pathophysiology of BPHOnly 14 pages are availabe for public view
 |  | from | 146 |  |  |
| | | from | 146 | | |
Abstract
Background: Benign prostatic hyperplasia (BPH) is a disorder histologically characterized as the non-malignant hyperplasia of prostatic cells most of patients with benign prostate hyperplasia present with lower urinary tract symptoms(LUTS). Erectile dysfunction (ED) is defined as the persistent or recurrent inability to achieve & maintain an erection sufficient for satisfactory sexual performance. Lower urinary tract symptoms (LUTS), benign prostate hyperplasia (BPH), and erectile dysfunction (ED) are highly prevalent entities in aging men.
Objective: To assess the efficacy and safety of fixed-dose of tadalafil or Tamsulosin versus their combination in treatment for BPH patient and erectile dysfunction (ED) by comparing IPSS score, PVR, Q max and The international Index of Erectile Function (IEED questionnaire)
Patients and Methods: In our analysis the aim of our study to assess the efficacy and safety of fixed-dose combinations therapy of Tamsulosin 0.4 mg plus Tadalafil 5mg versus Tadalafil 5mg alone or tamsulosin 0.4 mg alone once daily in treatment for BPH patient with lower urinary tract symptoms (LUTS) and erectile dysfunction (ED). In this prospective randomized clinical study one hundred and Fifty patients >45 years old complaining of LUTS due to BPH and erectile dysfunction were randomly divided into three groups.
Results: This suggests that the new fixed-dose combinations therapy can offer clinically relevant benefits for patients with LUTS complaints and desiring amelioration for comorbid ED complaints.
Conclusion: The study shows that the fixed- dose combination of Tamsulosin 0.4 mg/day and Tadalafil 5 mg/day are significantly superior to Tadalafil 5 mg/day or tamsulosin 0.4 mg / day alone for the treatment of BPH patients with LUTS and and non-inferiority in ED treatment in comparison to Tadalafil alone Without showing any clinically significant safety issues, supporting favourable benefit-risk balance of the fixed-dose combinations of therapy for the treatment of BPH patients with LUTS and ED because of its synergistic effects, well tolera¬tion and its safety.